Kynexis has closed a €40 million Series A extension bringing the company’s total Series A financing to €97 million ($110 million). The financing was led by new investor Novartis Venture Fund, with participation from existing investors Forbion, Ysios Capital, and Sunstone Life Science Ventures. In connection with the financing, Novartis Venture Fund’s Marianne Uteng has […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!